Dissertation/Thesis Abstract

Pegylation of an anti-methamphetamine scFv: Pharmacokinetic and neurological implications
by Reichard, Emily E., Ph.D., University of Arkansas for Medical Sciences, 2015, 129; 3704061
Abstract (Summary)

Methamphetamine (METH), one of the top drug problems in the United States, has a large number of biological targets, with the most critical targets located in the brain. The range of neurological effects METH can elicit is wide, and the majority of these effects are either rewarding or toxic. Despite this fact, there are no pharmacological treatments for METH abuse that are approved by the FDA. Therefore, we generated an anti-METH single chain antibody fragment (scFv7F9Cys) as a pharmacological treatment option for METH abuse. However, based on its size, scFv7F9Cys will likely have a short half-life in vivo, which would limit the potential use of scFv7F9Cys to the treatment of METH overdose. Thus, the aim of this dissertation was to create a longer lasting form of scFv7F9Cys through conjugation to poly(ethylene) glycol (PEG) (scFv7F9Cys-PEG), to evaluate the change in half-life using pharmacokinetic analysis, and to determine whether the extension in half-life will provide better protection against METH-induced neurological changes.

The goal of the first major aim was to test the in vitro effects of conjugating scFv7F9Cys to three different PEG’s, linear 5 kDa and 20 kDa PEGs, and a branched 40 kDa PEG. ScFv7F9Cys-PEG5K was conjugated but then unable to be purified, and thus was eliminated from future studies. The 40 kDa PEG was conjugated and purified; however, scFv7F9Cys-PEG40K displayed a loss of METH binding activity in vitro. Therefore, it was eliminated from pharmacokinetic analysis. The 20 kDa conjugate was purified and bound to METH with no change in affinity compared to scFv7F9Cys in vitro, suggesting PEGylation did not alter METH binding affinity. Therefore, the evaluation of scFv7F9Cys-PEG20K was extended to in vivo pharmacokinetic studies.

Pharmacokinetic parameters of scFv7F9Cys and scFv7F9Cys-PEG20K were then tested in an in vivo rat model for the second major aim. Rats were administered METH (3.2 mg/kg/day, s.c.) and treated with either scFv7F9Cys, scFv7F9Cys-PEG20K, or saline (30 mg/kg, i.v.) containing a radiolabeled tracer. Blood samples were taken at multiple time points after therapeutic protein administration and analyzed for therapeutic protein concentrations (scintillation counting) and METH concentrations (LC-MS/MS). Our results indicate PEGylation increased the serum half-life of scFv7F9Cys by 27-fold. Furthermore, PEGylation significantly extended scFv7F9Cys’s ability to alter METH disposition back into the serum from a 2 hour increase in METH serum concentrations to a 48 hour increase.

The effects of these pharmacokinetic antagonists on METH neurotoxicity markers have not been tested. Therefore, the purpose of the third major aim was to determine the effects of chronic administration of METH with scFv7F9Cys or scFv7F9Cys-PEG20K on three markers of the dopaminergic system: dopamine transporter (DAT), tyrosine hydroxylase (TH), and VMAT2; and three markers in the glutamatergic system: NMDA receptor (NR2A), AMPA receptor (GluR2), and PSD-95. Brain samples were harvested 144 hours post-pump implantation (METH administration), flash frozen, and pulverized into a fine powder. The pulverized brain tissue was then processed for qRT-PCR and Western blot analysis for all six markers. qRT-PCR results showed a significant reduction in TH, NR2A, GluR2, and PSD-95 mRNA expression in the scFv7F9Cys and scFv7F9Cys-PEG20K treatment groups. However, Western blotting revealed that only TH protein levels were significantly reduced in the scFv7F9Cys-PEG20K group. These unexpected findings will be the basis for further study of the relationship of anti-METH scFvs and neuronal markers of toxicity.

Indexing (document details)
Advisor: Peterson, Eric C.
Commitee: Gottschall, Paul E., Owens, S. Michael, Rusch, Nancy J., Waterhouse, Barry D.
School: University of Arkansas for Medical Sciences
Department: Pharmacology
School Location: United States -- Arkansas
Source: DAI-B 76/09(E), Dissertation Abstracts International
Source Type: DISSERTATION
Subjects: Pharmacology
Keywords: Meth, Methamphetamine, scFv7F9Cys
Publication Number: 3704061
ISBN: 9781321762174
Copyright © 2019 ProQuest LLC. All rights reserved. Terms and Conditions Privacy Policy Cookie Policy
ProQuest